Assessing InnoCare Pharma (SEHK:9969) Valuation After Its 2025 Profit Turnaround

Earnings shift draws fresh attention to InnoCare Pharma

InnoCare Pharma (SEHK:9969) has drawn fresh attention after reporting full year 2025 sales of CN¥2,374.91 million and net income of CN¥642.47 million, compared with a net loss a year earlier.

See our latest analysis for InnoCare Pharma.

The earnings swing has coincided with strong price momentum, with a 31.19% 1 month share price return and a 24.16% year to date share price return at HK$15.52. The 1 year total shareholder return of 102.08% contrasts with a 5 year total shareholder return decline of 19.17%, hinting that sentiment has improved recently but remains shaped by a longer mixed experience.

If this kind of turnaround story has caught your eye, it could be a good moment to see which other healthcare names are gaining attention through our 127 healthcare AI stocks

With earnings now in the black, a value score of 5, an intrinsic discount of 52.35% and a 36.25% gap to analyst targets, the key question is whether there is still a buying opportunity, or if the market is already pricing in future growth.

Most Popular Narrative: 27% Undervalued

InnoCare Pharma’s most followed narrative points to a fair value of HK$21.27 against a last close of HK$15.52, indicating a wide valuation gap built on detailed growth and margin assumptions.

The analysts have a consensus price target of HK$15.606 for InnoCare Pharma based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of HK$25.79, and the most bearish reporting a price target of just HK$8.2.

Read the complete narrative.

There is a full earnings roadmap sitting behind that fair value, including revenue growth assumptions, margin shifts and a punchy future earnings multiple. Curious which levers matter most and how sensitive the story is to small changes in those inputs?

Result: Fair Value of HK$21.27 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, the story can unravel quickly if high R&D spending does not translate into successful launches, or if reliance on a few key drugs leaves earnings exposed.

Find out about the key risks to this InnoCare Pharma narrative.

Another View: What The P/E Gap Is Telling You

That 27% undervalued fair value of HK$21.27 sits alongside a very different signal from the current P/E of 36x, compared with a fair ratio of 9.6x. The stock also trades below the Asian Biotechs average of 38.9x and the peer average of 52.1x, which mixes value support with clear valuation risk if sentiment cools.

For anyone weighing these mixed messages, the key question is whether the current P/E is closer to a ceiling that could compress toward the fair ratio, or a stepping stone if the growth story holds together.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Sentiment here is split, with solid recent returns set against real questions about valuation and earnings durability. Take a moment to look through the full data, stress test your own assumptions, then weigh up the 4 key rewards and 1 important warning sign

Looking for more investment ideas?

If InnoCare Pharma has caught your attention, do not stop here. Broaden your watchlist now and give yourself more options before the next big move.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com